CS-101

N/A

Report date: 2025/07/30 13:53:52

Base Information

Drug NameCS-101
Drug Alias NameCS-101
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionStem cell replacementsB-cell lymphoma/leukemia 11A modulators
TargetsB-cell lymphoma/leukemia 11A
Therapy Area/IndicationsGenetic Diseases, Inbornbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCorrectSequence Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCorrectSequence Therapeutics Co LtdZhengxu (Shanghai) Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGenetic Diseases, Inbornbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A